Research Funding

FY15 Extremity Regeneration Intervention


Pre-Application Deadline: 5:00 p.m. Eastern time (ET), December 15, 2015

Application Submission Deadline: 11:59 p.m. ET, December 22, 2015

Independent extramural investigators at all academic levels (or equivalent)

  • Supports Phase I, II, or pivotal clinical trial phase development projects focused on extremity regeneration.
  • The focus is on bone and soft tissue reconstruction, limb and tissue salvage technologies, and regenerative medicine technologies for the treatment of trauma-induced damage.
  • Must specifically address one or both of the FY15 Focus Areas.
  • Funding from this award mechanism must support a clinical trial and development-related efforts and may not be used for preclinical research studies.
  • The maximum period of performance is 4 years.
  • The maximum allowable funding (total costs) for the entire period of performance is $4.9 Million.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the website. The application package containing the required forms for each award mechanism can also be found on A listing of all CDMRP funding opportunities can be obtained on the website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government’s single-entry portal, Requests for email notification of the Program Announcements release may be sent to For more information about the PRORP or other CDMRP-administered programs, please visit the CDMRP website (

The JPC-8/CRMRP is one of six major DHP core research program areas within the DHP DHA RDA Directorate and is administered with oversight from JPC-8, which consists of Department of Defense (DoD) and non-DoD medical and military technical experts relevant to the program area. The JPC-8/CRMRP focuses on innovations to reconstruct, rehabilitate, and provide definitive care for injured Service members. The ultimate goal is to return the Service members to duty and restore their quality of life. Innovations developed from JPC-8/CRMRP-supported research efforts are expected to improve restorative treatments and rehabilitative care to maximize function for return to duty (RTD) or civilian life. The interest is in medical technologies (drugs, biologics, and devices) and treatment/rehabilitation strategies (methods, guidelines, standards, and information) that will significantly improve the medical care provided to our wounded Service members within the DoD health care system. Implementation of these technologies and strategies should improve the rate of RTD of Service members, the time to RTD, clinical outcome measures, and quality of life, as well as reduce the hospital stay lengths, clinical workload (patient encounters, treatments, etc.), and initial and long-term costs associated with restorative and rehabilitative or acute care.

Point of Contact:

CDMRP Help Desk 301-682-5507

Leave a Reply

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.